Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test
Status:
Unknown status
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
Preliminary evidence suggests that treatment with rifaximin may be beneficial in patients
with papulopustular rosacea.
The present clinical trial is aimed to investigate the safety and efficacy of oral rifaximin
delayed release versus placebo in adults with moderate-to-severe papulopustular rosacea
(a.k.a. subtype II) and positive lactulose H2/CH4 breath test.